Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib

Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting

AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial

First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

SPARC announces results from planned interim analysis of PROSEEK Study

Evonik unveils latest global trial results MetAMINO

Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg